David P. Schenkein - Feb 27, 2024 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Director
Signature
/s/ William Cook, as Attorney-in-fact for David Schenkein
Stock symbol
AGIO
Transactions as of
Feb 27, 2024
Transactions value $
-$210,022
Form type
4
Date filed
2/29/2024, 04:05 PM
Previous filing
Feb 27, 2024
Next filing
Jun 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $375K +11.9K +9.65% $31.64 135K Feb 27, 2024 Direct
transaction AGIO Common stock Sale -$398K -11.9K -8.8% $33.60 123K Feb 27, 2024 Direct F1
transaction AGIO Common stock Options Exercise $1.82M +57.5K +46.78% $31.64 180K Feb 27, 2024 Direct
transaction AGIO Common stock Sale -$2.01M -57.5K -31.87% $34.89 123K Feb 27, 2024 Direct F2
holding AGIO Common stock 271K Feb 27, 2024 See footnote F3
holding AGIO Common stock 79.1K Feb 27, 2024 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Stock option (right to buy) Options Exercise $0 -11.9K -17.1% $0.00 57.5K Feb 27, 2024 Common stock 11.9K $31.64 Direct F5
transaction AGIO Stock option (right to buy) Options Exercise $0 -57.5K -100% $0.00* 0 Feb 27, 2024 Common stock 57.5K $31.64 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $33.02 to $34.41. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F2 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $34.64 to $35.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F4 Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
F5 This option was originally granted on March 5, 2014 for the purchase of 148,770 shares of common stock. The shares underlying this option vested as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.